FOSRENOL® (lanthanum carbonate)

Receive Our Newsletter

Invalid E-mail

X

You entered an invalid e-mail address Continue

Start Noncalcium Binder Therapy With FOSRENOL

Dosing and Administration of FOSRENOL¹

Recommended starting total daily dose is 1500 mg - one 500-mg tablet per meal*
Titrate as needed with 500-mg, 750-mg, or 1000-mg tablets^†
Chew or crush tablets completely before swallowing. Do not swallow intact tablets. Consider crushing tablets completely for patients with poor dentition.

* Dosing based on 3 meals per day. Number of meals per day may vary. To achieve certain doses, additional tablets may be required.

^† Dosing should be titrated every 2 to 3 weeks until an acceptable serum phosphorus level is reached. Monitor serum phosphorus levels as needed during dose titration and on a regular basis thereafter. Doses were generally titrated in increments of 750 mg/day. In clinical studies, most patients required a total daily dose of between 1500 mg and 3000 mg to reduce serum phosphorus levels to <6.0 mg/dL.

FOSRENOL^® Can Be Crushed to Aid in Chewing¹

Chew completely if taken as an intact tablet; do not swallow tablets whole
Take with or immediately after meals and do not take on an empty stomach

Indication

FOSRENOL is indicated to reduce serum phosphate in patients with end stage renal disease.

Important Safety Information

FOSRENOL is contraindicated in patients with bowel obstruction, ileus, and fecal impaction.
Serious cases of gastrointestinal obstruction, ileus, and fecal impaction have been associated with lanthanum use, some requiring surgery or hospitalization. Risk factors include altered gastrointestinal anatomy, hypomotility disorders, and concomitant medications.
Advise patients to chew or crush the tablet completely to reduce the risk of adverse gastrointestinal events. Advise patients with poor dentition that they may crush tablets completely. Advise patients to take FOSRENOL with or immediately after meals.
Patients with acute peptic ulcer, ulcerative colitis, Crohn's disease, or bowel obstruction were not included in FOSRENOL clinical studies.
FOSRENOL has radio-opaque properties and may give the appearance typical of an imaging agent during abdominal X-ray procedures.
The most common reactions seen with FOSRENOL in clinical trials included nausea, vomiting, diarrhea, and abdominal pain.
There is potential for FOSRENOL to interact with (1) compounds that bind to cationic antacids (ie, aluminum-, magnesium-, or calcium-based agents), (2) oral quinolone antibiotics, and (3) thyroid replacement medication; therefore, such concomitant medications should be dosed separately from FOSRENOL to avoid drug interactions. See specific dosing recommendations in the full Prescribing Information.
No adequate and well-controlled studies have been conducted in pregnant women and pediatric patients. FOSRENOL is not recommended for use during pregnancy.
The safety of lanthanum carbonate excreted in human milk is unknown. Caution should be exercised when FOSRENOL is administered to a nursing woman.
The use of FOSRENOL in the pediatric population is not recommended.

Please see Full Prescribing Information.

Reference(s):

FOSRENOL [package insert]. Wayne, PA: Shire US Inc.; 2011.

Social Media Tools

Site Navigation

FOSRENOL^® is registered with the US Patent and Trademark Office.
FOSRENOL On Track™ is a trademark of Shire LLC.
This site is strictly intended for US residents and is governed solely by US laws and governmental regulations.
Please see our online privacy policy for more information. While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy.
Shire US Inc. assumes no liability for any errors or omissions in the content of the site.
©2011 Shire US Inc. Wayne, PA 19087. 1-800-828-2088. All rights reserved.
FOS-01436 12/11